SAN - Banco Santander, S.A.

NYSE - Nasdaq Real Time Price. Currency in USD
4.6922
-0.1378 (-2.85%)
As of 11:06AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close4.8300
Open4.7100
Bid4.6800 x 38800
Ask4.6900 x 1800
Day's Range4.6700 - 4.7300
52 Week Range4.5000 - 7.5700
Volume2,585,924
Avg. Volume7,855,666
Market Cap75.757B
Beta (3Y Monthly)1.07
PE Ratio (TTM)9.73
EPS (TTM)0.4820
Earnings DateJan 25, 2017 - Feb 1, 2017
Forward Dividend & Yield0.16 (3.34%)
Ex-Dividend Date2018-10-16
1y Target Est6.05
Trade prices are not sourced from all markets
  • BBVA or SAN: Which Is the Better Value Stock Right Now?
    Zacks2 hours ago

    BBVA or SAN: Which Is the Better Value Stock Right Now?

    BBVA vs. SAN: Which Stock Is the Better Value Option?

  • GlobeNewswire4 days ago

    Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness

    November 16, 2018 - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness. This approval is a result of clinical trials led by the non-profit research and development organization DNDi and an application submitted by Sanofi.

  • Bolsonaro Taps Santander's Campos for Brazil's Central Bank
    Bloomberg5 days ago

    Bolsonaro Taps Santander's Campos for Brazil's Central Bank

    Campos Neto, Treasury director for the Americas at Banco Santander, will replace Ilan Goldfajn, according to a text message from incoming Finance Minister Paulo Guedes. The appointment needs to be approved by Congress.

  • Why Banco Santander Brasil Shares Soared 29% in October
    Motley Fool9 days ago

    Why Banco Santander Brasil Shares Soared 29% in October

    Brazilian politics provided an external boost to Santander's share price -- at least temporarily.

  • GlobeNewswire9 days ago

    Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause

    November 11, 2018 - New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific Sessions 2018. Praluent® (alirocumab) was associated with fewer deaths from any cause among patients who had previously experienced a heart attack or unstable angina (known as acute coronary syndrome, or ACS), and this was enhanced in patients who were followed for at least 3 years and those who had an LDL-C (low-density lipoprotein cholesterol) of 100 mg/dL or higher at baseline.

  • GlobeNewswire13 days ago

    New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial

    New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial Praluent significantly reduced major adverse.

  • Spain to Change the Law to Make Banks Pay for Stamp Duty
    Bloomberg13 days ago

    Spain to Change the Law to Make Banks Pay for Stamp Duty

    The government announcement was a response to the popular and political outrage that followed a court decision last night that home buyers should pay the tax. Prime Minister Pedro Sanchez said the government regrets the Supreme Court decision handed down late Tuesday, and that it will make banks pay the tax from the moment it publishes a decree on the matter. “Never again will Spaniards pay the tax,” Sanchez said at a news conference in Madrid on Wednesday.

  • GlobeNewswire14 days ago

    FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

    November 6, 2018 - The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with moderate-to-severe atopic dermatitis.

  • The Wall Street Journal19 days ago

    [$$] Turkey Doesn't Have to Be a Disaster for Banks

    Bank investors seem to be spooked by Turkey, but they may be overreacting. That is one lesson you could draw from the share-price reactions to third-quarter results from two Spanish banks.

  • GlobeNewswire19 days ago

    Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases

    November 1, 2018 - Sanofi plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to treat a range of neurological and systemic inflammatory diseases. The two lead molecules (DNL747 and DNL758) target a critical signaling protein known as the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.

  • Simply Wall St.20 days ago

    Does Banco Santander SA’s (BME:SAN) P/E Ratio Signal A Buying Opportunity?

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how Banco Santander SA’s (BME:SAN) Read More...

  • CNBC20 days ago

    European markets extend comeback to close higher but October losses weigh

    European stocks rallied Wednesday as investors digested further corporate earnings.

  • Santander Meets Capital Goal Amid Surge in Quarterly Profit
    Bloomberg20 days ago

    Santander Meets Capital Goal Amid Surge in Quarterly Profit

    Key HighlightsA positive surprise was the building of capital with 31 basis points added to fully-loaded core equity Tier 1 in the quarter, taking the measure to 11.11 percent. The election of Jair Bolsonaro has raised hopes he’ll implement reforms that will boost Santander’s largest market, and the real has recently pared losses.The U.K. showed signs of stabilizing after a tough regulatory environment and uncertainty surrounding Brexit weighed on the business in prior quarters. Santander has had to invest money in projects such as ring-fencing, which obliges banks to separate investment arms from retail banking.

  • GlobeNewswire20 days ago

    Sanofi Q3 2018 Performance Confirms Return to Growth

    Paris, October  31, 2018 Sanofi Q3 2018 Performance Confirms Return to Growth   Q3 2018 Change Change at CER 9M 2018 Change.

  • The Wall Street Journal20 days ago

    [$$] Santander Profit Surges

    Banco Santander SA’s (SAN.MC) third-quarter net profit grew strongly from a year earlier, when it reported a number of one-off charges. Net profit for the period rose roughly 36% to 1.99 billion euros ($2.

  • CNBC20 days ago

    Santander posts earnings in line with expectations as third-quarter profits surge

    The euro zone's largest bank by market value posted attributable net profit of 1.99 billion euros ($2.256 billion) for the three-month period ending Sept. 30. Analysts at data firm Refinitiv had been expecting third-quarter net profit to come in at around 1.98 billion euros. Like Spanish rival BBVA, Santander makes most of its profit overseas, a model that has helped the bank counter a double-dip recession at home in recent years.

  • OSVBF vs. BSAC: Which Stock Is the Better Value Option?
    Zacks28 days ago

    OSVBF vs. BSAC: Which Stock Is the Better Value Option?

    OSVBF vs. BSAC: Which Stock Is the Better Value Option?

  • GlobeNewswirelast month

    Sanofi: FDA approves asthma indication for Dupixent® (dupilumab)

    FDA approves asthma indication for Dupixent® (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic.

  • GlobeNewswirelast month

    Sanofi receives positive CHMP opinion for dengue vaccine

    Dengue fever is a debilitating disease typically leading to prolonged fever and severe joint pain. Dengue infection can progress unpredictably to a life-threatening form of the disease called dengue haemorrhagic fever that often requires hospitalized care. Today, there is no specific treatment available for dengue disease.

  • Seven international banks agree to launch digital trade finance network
    Reuterslast month

    Seven international banks agree to launch digital trade finance network

    Seven banks, including HSBC (HSBA.L) and Banco Santander (SAN.MC), have signed a Memorandum of Understanding (MoU) to create a global digital network in trade finance aiming at allowing cheaper and easier funding for corporates, a Santander manager said on Wednesday. The Australia and New Zealand Banking Group ANZ (ANZ.AX), BNP Paribas (BNPP.PA), Citibank (C.N), Standard Chartered and Deutsche Bank (DBKGn.DE) also agreed to join the digital trade information network expected to be operational by the third quarter of next year. "It is the first time that these banks come together to set a standard (...) that will allow cheaper access to finance because the risks are going to be reduced," Rogier Schulpen, global head of trade and working solutions at Banco Santander, said in a phone interview.

  • GlobeNewswirelast month

    Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

    Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps Dupixent significantly reduced nasal.

  • Ripple's cryptocurrency product goes live for the first time with three financial firms
    CNBC2 months ago

    Ripple's cryptocurrency product goes live for the first time with three financial firms

    Ripple said that xRapid, which uses the cryptocurrency XRP to carry out international transactions, is now commercially available.

  • Simply Wall St.2 months ago

    Have You Considered These Important Risk Metrics For Banco Santander SA (BME:SAN)?

    With a €72.18b market capitalisation, Banco Santander SA (BME:SAN) falls in the large, commercial bank category. A common risk large financial institutions face is credit risk, measured by the level Read More...

  • The Wall Street Journal2 months ago

    [$$] Santander Names UBS Investment Bank Head Andrea Orcel as Next CEO

    Banco Santander SA named UBS Group AG’s Andrea Orcel as its new CEO, propelling one of Europe’s highest-profile investment bankers to the helm of a global banking giant. Santander said Mr. Orcel will take over early next year from José Antonio Álvarez, who has been in the job since 2015. Mr. Álvarez will become vice chairman of the Santander group and executive chairman for Santander Spain, the bank said.